Fitterfly presents outcomes from Digital Therapeutics Platform at 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023), Germany

At this prestigious event, Dr Arbinder Singal Co-founder and CEO and Shailesh Gupta Co-founder and COO, presented two research papers highlighting the real-world effectiveness of Fitterfly Diabetes CGM Digital Therapeutics Program for improvement in glycemic control and metabolic parameters of people with T2DM.Fitterflys first presentation focused on how their Digital Therapeutics solutions were able to benefit the participants through use of CGM-led behavior change, and personalized lifestyle changes during the 90-day program.